Target intelligence / Profile preview

Transcription elongation factor SPT6 (SUPT6H)

Target: SUPT6H
Molecular classification: Histone chaperone, Transcription elongation factor, Chromatin regulatory protein, "Other" (occasionally classified as "chromatin remodeler" or "epigenetic regulator")

Overview

Transcription elongation factor SPT6 (SUPT6H) is a highly conserved eukaryotic protein that functions as both a histone chaperone and a transcription elongation factor. It is essential for productive gene expression mediated by RNA polymerase II. SPT6 enhances polymerase elongation rates, facilitates polymerase progression through nucleosomal barriers, and coordinates nucleosome disassembly/reassembly during transcription. It maintains chromatin structure, coordinates key histone modifications (e.g., H3K4me3, H2Bub), and supports proper transcription termination and mRNA processing. Beyond transcription, SPT6 contributes to DNA replication, genome stability, and fidelity of transcription initiation, with critical roles in development across metazoans. Its loss or dysfunction is implicated in human cancers and developmental disorders, reflecting its broad biological importance and the risk of therapeutic targeting.

Other names: SUPT6HTat-CT2 proteinKIAA0162SPT6HhSPT6Histone chaperone suppressor of Ty6Tat-cotransactivator 2 proteinSPT6emb-5suppressor of Ty 6 homolog

Mechanism of action

Not applicable due to lack of direct drug modulators known

Biological functions

Transcription elongation (promotes RNA polymerase II processivity, facilitates pause release, aids progression through nucleosomal DNA)Chromatin structure regulation and nucleosome assembly/reassemblyHistone modification coordination (e.g., regulates H3K4 trimethylation and H2B monoubiquitination)mRNA processing and transcription terminationDNA replicationGenome stability and integrity maintenanceCellular differentiation and development

Disease associations

Cancer (linked to cancer types in humans)Developmental disorders (required for proper tissue development in model organisms and mammals)Other roles likely in epigenetic dysregulation and immune functions (e.g., class-switch recombination)

Safety considerations

As an essential gene for chromatin integrity and cell viability, direct inhibition or knockout could cause cell death or developmental defectsPotential toxicity if targeted, due to widespread roles in transcription and genome stabilityTumorigenic or epigenetic consequences possible if dysregulated

Interacting drugs

No known approved drugs currently directly target SUPT6H/SPT6 as a primary mechanism (based on current public resources)

Biomarkers

Not established as a clinical biomarker for patient selection or efficacy monitoringPossible utility in experimental cancer research or transcriptional profiling as a marker of elongation and chromatin status

Beyond the preview

Go deeper on Transcription elongation factor SPT6 (SUPT6H).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcription elongation factor SPT6 (SUPT6H).

Explore the full profile